TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03452137

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Atezolizumab
Description: Atezolizumab intravenous infusion will be administered at a fixed dose on Day 1 of each 21-day cycle for 16 cycles.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo intravenous infusion will be administered a fixed dose on Day 1 of each 21-day cycle for 16 cycles.
Study: NCT00641225

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SBI-087
Description: Single IV doses of SBI-087 from 0.015 mg/kg to 2 mg/kg and Single SC doses of SBI-087 from 50 mg to 300 mg.
Study: NCT03044626

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Radiotherapy
Description: Nivolumab 240 mg fixed dose (q2w). First dose followed by radiotherapy. Radiotherapy has to start at the latest 72 hours after nivolumab administration.~Radiotherapy: A metastatic site will be treated with a radiation dose of 4 Gy for a total of 5 courses during a two week time interval (total dose 20 Gy)
Study: NCT02192632

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Epiduo- once daily, simple instruction for application

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: BPO once daily
Study: NCT03044626

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Nivolumab 240 mg fixed dose (q2w)

Intervention type: DRUG
Group type: OTHER
Intervention: Nivolumab
Description: Nivolumab 240 mg fixed dose (q2w)
Study: NCT00794339

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 64Cu-ATSM

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FDG
Study: NCT02420912

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ibrutinib
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ibrutinib
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ibrutinib
Description: Given PO

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Given IV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Given IV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Given IV
Study: NCT01097512

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AS703569/gemcitabine
Description: Gemcitabine on Days 1 and 8, AS703569 on Days 2 and 9, of a 21-day cycle. The starting dose (DL1) for AS703569 will be 10mg/m2/day. The subsequent dose levels of AS703569 will follow the dose-escalation scheme with an approximate 50% increase from DL1 to DL2, 40% from DL2 to DL3, and thereafter an approximate increase of 33% from one dose level to the next.~Gemcitabine will be administered at the dose of 1000mg/m2 once weekly during the first two weeks of each 21-day cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AS703569/gemcitabine
Description: AS703569 on Days 1 and 8, gemcitabine on Days 2 and 9, of a 21-day cycle. The starting dose (DL1) for AS703569 will be 10mg/m2/day. The subsequent dose levels of AS703569 will follow the dose-escalation scheme with an approximate 50% increase from DL1 to DL2, 40% from DL2 to DL3, and thereafter an approximate increase of 33% from one dose level to the next.~Gemcitabine will be administered at the dose of 1000mg/m2 once weekly during the first two weeks of each 21-day cycle.
Study: NCT02418832

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Sperm cell aspiration and TEFNA
Description: Testicular Fine Needle Aspiration (TEFNA)
Study: NCT03546127

Intervention type: GENETIC
Intervention: Next Generation Sequencing (NGS): exome, RNA seq
Description: Tumor and blood samples will be sequenced at medium-high coverage at the whole genome (exome) and transcriptome levels (RNA Seq). This will allow detecting variants in a larger set of samples even though only from the main clone will be precisely measured. The whole exome will be performed at a mean coverage of at least 60x for the normal DNA samples and 120x for the tumor DNA samples. The transcriptome of the tumor will be performed at enough depth of coverage to detect gene fusions, transcriptome variants and measure the digital expression of already annotated isoforms.~For both sequencing configurations:~* Data from each cancer and normal genome will be analysed for the presence of somatic variants.~* DNA and RNA sequencing results will be integrated.~* Technical replication for the mutations / chromosome alterations / transcript fusions that most likely drive the tumour process will be performed via Target Resequencing of the genomic / coding regions of interest.

Intervention type: GENETIC
Intervention: Next Generation Sequencing (NGS): exome, RNA seq
Description: Tumor and blood samples will be sequenced at medium-high coverage at the whole genome (exome) and transcriptome levels (RNA Seq). This will allow detecting variants in a larger set of samples even though only from the main clone will be precisely measured. The whole exome will be performed at a mean coverage of at least 60x for the normal DNA samples and 120x for the tumor DNA samples. The transcriptome of the tumor will be performed at enough depth of coverage to detect gene fusions, transcriptome variants and measure the digital expression of already annotated isoforms.~For both sequencing configurations:~* Data from each cancer and normal genome will be analysed for the presence of somatic variants.~* DNA and RNA sequencing results will be integrated.~* Technical replication for the mutations / chromosome alterations / transcript fusions that most likely drive the tumour process will be performed via Target Resequencing of the genomic / coding regions of interest.
Study: NCT02389231

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Interleukine-2
Description: Four courses of IL2 ( \[Proleukin, Novartis\]) will be administered subcutaneously for 5 days.~The first course will be limited to a dose of 1.5 million IU per day and followed by a 9 day wash-out.~The other courses of 3 million IU per day will be initiated after a 16 day wash-out.
Study: NCT01246635

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Trufit CB (Cartilage Bone) Implant
Description: Implantation of 5,7, 9, or 11 mm Trufit CB Implants for small cartilage lesions. A maximum of two Trufit CB plugs may be implanted.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Trufit CB (Cartilage Bone) Implant
Description: Implantation of 5,7, 9, or 11 mm Trufit CB Implants for small cartilage lesions. A maximum of two Trufit CB plugs may be implanted.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Microfracture if the knee
Description: Creation of small holes through subchondral bone with the goal of stimulating cartilage growth
Study: NCT04436549

Intervention type: PROCEDURE
Intervention: Stab Avulsion of varicose veins
Description: Stab avulsion is a technique to remove varicose veins. In this procedure, several tiny cuts (incisions) are made in the skin through which the varicosed vein is removed. Removed varicose veins will be collected and analyzed.

Intervention type: DIAGNOSTIC_TEST
Intervention: Histopathologic evaluation of varicose veins
Description: Sample obtained from varicose veins of lower limbs of patients will be collected and immediately fixed in formalin. The tissue fragments will be taken from varicose veins. Subsequently the tissue will be embedded in paraffin and 3-to-4 mm thick sections will be prepared by a microtome. The tissue sections will be processed for histological and immunohistochemical studies of VEGF, MM9, PGP 9.5 AND FRIBRONECTIN. For antibodies the EnVision staining system (Dako EnVision™) will be used. For the analysis of the positive structures detected by immunohistochemistry, a semiquantitative evaluation method will be used.
Study: NCT03054766

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Ranibizumab combined macular laser
Description: subjects in one group receive both macular laser photocoagulation and ranibizumab injections but ones in the other group just received ranibizumab injection.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ranibizumab
Description: all subjections received 3+PRN ranibizumab injections by BCVA stabilization

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ranibizumab
Description: all subjections received 3+PRN ranibizumab injections by BCVA stabilization
Study: NCT04062578

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Physiotherapy program of lumbopelvic stabilization and strengthening of the hip region musculature
Description: The intervention program will begin in August, along with the 2019/2020 season, and will finish at the end of the first round (5-6 months). It will be applied to CD Oliver players in three weekly sessions: preventive force, compensatory force and physiotherapy attention. During this intervention period, the SD Huesca players, control group, continued with their usual training program. They will not implement any physiotherapy program like the designed one for the study.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Physiotherapy program of lumbopelvic stabilization and strengthening of the hip region musculature
Description: The intervention program will begin in August, along with the 2019/2020 season, and will finish at the end of the first round (5-6 months). It will be applied to CD Oliver players in three weekly sessions: preventive force, compensatory force and physiotherapy attention. During this intervention period, the SD Huesca players, control group, continued with their usual training program. They will not implement any physiotherapy program like the designed one for the study.
Study: NCT00937807

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: xenon
Description: Inhalational gas; dose allowed: 60 % Xenon; the duration of the treatment will be defined through anesthesia-time for a carotid surgery

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: sévoflurane
Description: Inhalation gas; dose allowed: 1,4 %; the duration of the treatment will be defined through anesthesia-time for a carotid surgery
Study: NCT04737993

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: licocain
Description: pulsed radiofrequency stimulation

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: licocain
Description: pulsed radiofrequency stimulation

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: licocain
Description: pulsed radiofrequency stimulation

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: pulsed radiofrequency stimulation
Description: pulsed radiofrequency stimulation of joint capsel

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: pulsed radiofrequency stimulation
Description: pulsed radiofrequency stimulation of joint capsel
Study: NCT03814226

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Evaluation of headache inducing capabilities of PACAP38
Description: We wish to investigate the headache inducing capabilities of PACAP-38, a vasoactive peptide, over a 20 minute infusion. As PACAP-38 casues visible vasodilation, another vasoactive peptide, called VIP will be used as an active comparator.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Evaluation of headache inducing capabilities of PACAP38
Description: We wish to investigate the headache inducing capabilities of PACAP-38, a vasoactive peptide, over a 20 minute infusion. As PACAP-38 casues visible vasodilation, another vasoactive peptide, called VIP will be used as an active comparator.
Study: NCT01386632

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: DCA (dichloroacetate)
Description: DCA orally 12.5mg/kg PO or per G-tube BID daily for 8 weeks in conjunction with Cisplatin 100 mg/m\^2 IV over 30-60minutes every 3wks X 3(Days 1, 22, and 43 of RT)and RT 70 Gy/35 -200 cGy/d x 7 weeks (35 Fractions)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo PO or per G-tube twice a day for 8 weeks given in combination with Cisplatin.
Study: NCT02337855

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Sm-TSP-2/Alhydrogel/GLA-AF
Description: Sm-TSP-2/Alhydrogel/GLA-AF. Group B: single dose intramuscular (IM) 10mcg Sm-TSP-2/Alhydrogel®/GLA-AF on Day 1, 57 and 113. Group E: single dose intramuscular (IM) 30mcg Sm-TSP-2/Alhydrogel®/GLA-AF on Day 1, 57 and 113. Group H: single dose intramuscular (IM) 100mcg Sm-TSP-2/Alhydrogel®/GLA-AF on Day 1, 57 and 113.
Study: NCT03684460

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Daytime Bright Light
Description: Daytime Bright Light (DBL) will be delivered by a free-standing apparatus set to deliver 10,000 lux. The device will be placed at the bedside within 36 inches of the patient's head and is expected to provide at least 1,250 lux at the angle of gaze. To remain in the study, the patient must be in the Intensive Care Unit (ICU) through 13:00 on day 2 (e.g., the first day of potential intervention). After day 2, DBL and other study activities will continue if the patient is transferred out of the ICU to the general medical floor.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Usual Light
Description: Usual care lighting in ICU.~To remain in the study usual care patients must also remain in the MICU through 13:00 on day 2.
Study: NCT03070262

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CA
Description: caffeic acid, 300mg, tid, po

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo group
Description: placebo tablet, 3 tablets, tid, po
Study: NCT02117024

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Viagenpumatucel-L
Description: Vaccine derived from irradiated human lung cancer cells genetically engineered to continually secrete gp96-Ig

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metronomic Cyclophosphamide
Description: One 50mg tablet administered orally daily for 7 days on alternating weeks for a total of 6 weeks of therapy over 12 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Physician's Choice Regimen (Vinorelbine, Erlotinib, Gemcitabine, Paclitaxel, Docetaxel, Pemetrexed)
Description: Physician will select one of the following to be given in nominal 21 day cycles with dose and route according to investigator's standard practice:~* Vinorelbine~* Erlotinib~* Gemcitabine~* Paclitaxel~* Docetaxel~* Pemetrexed
Study: NCT02094339

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Local analgesic
Description: Patient will be performed under combined lumbar plexus and sciatic nerve block with 0.33% ropivacaine.At the end of surgery,two catheters are left in the wound.One is intraarticular and the other is on the surface of articular cavity.And then a pump elastomeric infusion pump will be connected with the catheters, which runs 5mL every hours.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Nerve Block
Description: Combined lumbar plexus and sciatic nerve block with 0.33% ropivacaine will be performed before the surgery.After the a bolus of 30mL ropivacaine around lumbar plexus,a catheter will be left in Psoas gap with 6cm.A pump elastomeric infusion pump running 5mL every hours will also be connected with the catheters at the end of the operation.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Intravenous analgesic
Description: People in this group will also receive an anesthesia of combined lumbar plexus and sciatic nerve block with 0.33% ropivacaine.An intravenous electronic analgesia pump infusion of flurbiprofen axetil 250mg,palonosetron 0.5mg,pentazocine 240mg.dezocine 30mg will will provide postoperative pain management.The patients will received a 2 mL/h continuous basal infusion and 1 mL boluses with a lockout time of 30 min after a 5 mL Loading dose at the end of the surgery.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ropivacaine
Description: 0.2% ropivacaine

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ropivacaine
Description: 0.2% ropivacaine

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: opioid
Description: flurbiprofen axetil 250mg,palonosetron 0.5mg,pentazocine 240mg.dezocine 30mg
Study: NCT04572464

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Mindfulness Based Guided Meditation
Description: Mindfulness Based Guided Meditation will be practiced by nurses under the supervision of researcher for 15 min thrice a week for two weeks
Study: NCT04778995

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Structured online training program for effective management of nursing services
Description: An online structured training program was prepared to reach out to manager nurses for increasing their knowledge regarding the effective management of nursing services in crisis periods. A web page was structured with the support of a professional computer engineer.~Participant manager nurses could log into the system via a personal username and password on the main login screen of the site. In this page, there is an Informed Consent Form.~In the Download Training Documents link; the educational content prepared in sections was presented. Educational content consisted of the issues such as: Management of Crises and Emergency Situations, Leadership in Crisis, Planning and Managing Nurse Human Power in Crisis, Supervision and Management of Patient Care, Logistics and Support Services, Communication in Extraordinary Situations, Motivation Tools Used in Extraordinary Situations, Stress Management During Crisis and Employee Adaptation and Training in Crisis.
Study: NCT03268395

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Arterial Blood Gas and Transcutaneous CO2 Monitor
Description: Each patient will receive both an arterial blood gas and a transcutaneous CO2 monitor test.
Study: NCT00688649

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Standard Oral Nutritional Supplement (ONS)
Description: Standard energy, oral nutritional supplement (a milk style nutritional supplement (1.5kcal/ml, 200ml) containing protein, fat, carbohydrate and micronutrients)

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: High energy Oral Nutritional Supplement (ONS)
Description: High Energy nutritional supplement (a milk style nutritional supplement (2.4kcal/ml, 125ml) containing protein, fat, carbohydrate and micronutrients)
Study: NCT01591044

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 1 puff bid or 2 puffs bid

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: R940343 1mg
Description: R343 1mg, 1 puff bid

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: R940343 2mg
Description: R343 2mg, 2 puffs bid
Study: NCT03770078

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Test Product A
Description: The test product is a newly developed ostomy product
Study: NCT00799370

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Early weight bearing
Description: Weight bearing performed immediately after surgery

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Delayed weight bearing
Description: Weight bearing performed 2 months after surgery
Study: NCT04093115

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CX1106
Description: administration of CX1106 at 740 mg/m2 as a 24-hour continuous infusion for 5 days (120 h, d1-5), 21 days per cycle, no more than 6 cycles
Study: NCT01990339

Intervention type: DRUG
Intervention: Lansoprazole
Description: • Reflux esophagitis The usual adult dosage is 30 mg of lansoprazole administered orally once daily for up to 8 weeks.~For maintenance therapy of repeatedly recurring/relapsing reflux esophagitis, the dosage is 15 mg of lansoprazole administered orally once daily. If insufficient efficacy is observed, the dosage may be increased to 30 mg administered orally once daily.~• Nonerosive gastroesophageal reflux disease Non-erosive gastroesophageal reflux disease The usual adult dosage is 15 mg of lansoprazole administered orally once daily for up to 4 weeks.
Study: NCT02949297

Intervention type: DEVICE
Group type: OTHER
Intervention: Ovation Alto Abdominal Stent Graft System
Description: Repair of Abdominal Aortic Aneurysm with Ovation Alto Abdominal Stent Graft System
Study: NCT00674037

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: monetary incentive
Description: 75 euros for each patient included
Study: NCT02929758

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Speed of processing training (SOPT)
Description: This is a game-like program designed based on the UFOV. It consists of five activities (Sweep Seeker, Bird Safari, Jewel Diver, Master Gardener, and Road Tour). The duration of training will be 3 months. Participants will be encouraged to train at least three-times weekly for 1-hour blocks and must complete at least 20 training sessions over the course of the three months.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Speed of processing training (SOPT)
Description: This is a game-like program designed based on the UFOV. It consists of five activities (Sweep Seeker, Bird Safari, Jewel Diver, Master Gardener, and Road Tour). The duration of training will be 3 months. Participants will be encouraged to train at least three-times weekly for 1-hour blocks and must complete at least 20 training sessions over the course of the three months.

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Speed of processing training (SOPT)
Description: This is a game-like program designed based on the UFOV. It consists of five activities (Sweep Seeker, Bird Safari, Jewel Diver, Master Gardener, and Road Tour). The duration of training will be 3 months. Participants will be encouraged to train at least three-times weekly for 1-hour blocks and must complete at least 20 training sessions over the course of the three months.

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Speed of processing training (SOPT)
Description: This is a game-like program designed based on the UFOV. It consists of five activities (Sweep Seeker, Bird Safari, Jewel Diver, Master Gardener, and Road Tour). The duration of training will be 3 months. Participants will be encouraged to train at least three-times weekly for 1-hour blocks and must complete at least 20 training sessions over the course of the three months.
Study: NCT01043614

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: PEER group intervention
Description: An exercise and nutrition intervention that is based on self-efficacy principles and delivered primarily by peer educators to reduce the risk for obesity in female college freshman over one academic year